Twitter | Pretraživanje | |
Xconomy
Authoritative voice on biotech's exponential economy: news, events, awards, webinars, whitepapers, , , ,
22.703
Tweetovi
2.300
Pratim
27.031
Osobe koje vas prate
Tweetovi
Xconomy 54 min
Arcutis Bio Raises $159M in Upsized IPO to Test Skin Disease Drugs - by
Reply Retweet Označi sa "sviđa mi se"
Xconomy 1 h
Reply Retweet Označi sa "sviđa mi se"
Xconomy proslijedio/la je tweet
Frank Vinluan 1 h
ICYMI, won FDA approval Friday for , a peanut allergy therapy. The FDA decision covers kids 4-17 yrs.old...
Reply Retweet Označi sa "sviđa mi se"
Xconomy proslijedio/la je tweet
Frank Vinluan 1. velj
Odgovor korisniku/ci @aimmune
carries an $890 a month wholesale price before any rebates or discounts. But says it will offer payment assistant programs that could reduce the cost to as low as $20 a month. The new drug is expected to launch in coming weeks.
Reply Retweet Označi sa "sviđa mi se"
Xconomy proslijedio/la je tweet
Medtech by @LaForge_AI 19 h
Xconomy: BIO Report: More Work Needed to Improve Diversity at Biotech Firms via
Reply Retweet Označi sa "sviđa mi se"
Xconomy 31. sij
BIO Report: More Work Needed to Improve Diversity at Biotech Firms - by
Reply Retweet Označi sa "sviđa mi se"
Xconomy proslijedio/la je tweet
Frank Vinluan 31. sij
When it comes to , size matters. Here's why thinks the smaller size of Cas14 gives it advantages for developing new drugs and diagnostics
Reply Retweet Označi sa "sviđa mi se"
Xconomy 30. sij
[PARTNER EVENT] presents 7th annual Healthcare Investment Trends: Where Will the Money Flow in 2020? Use code HCVC-PARTNER for $25 discount on registration. REGISTER: Sponsored by
Reply Retweet Označi sa "sviđa mi se"
Xconomy 30. sij
Newly added speakers include: Ciara Kennedy of Chris Loryman of Russ Barrans of Josh Schimmer of Evercore
Reply Retweet Označi sa "sviđa mi se"
Xconomy 30. sij
With $45M, Expects Big Things From Tiny CRISPR Cas14 - by ; insight from CEO
Reply Retweet Označi sa "sviđa mi se"
Xconomy 30. sij
Black Diamond’s Upsized IPO Raises $201M to Advance Its Cancer Drug R&D - by
Reply Retweet Označi sa "sviđa mi se"
Xconomy 30. sij
Vizgen Launches With $14M to Market New Subcellular Imaging Technique - by
Reply Retweet Označi sa "sviđa mi se"
Xconomy 30. sij
Spun out the where Nancy Hopkins won the Lifetime Achievement Award, 3 scientists formed the Boston Biotech Working Group to "remedy the gender imbalance in biotech":
Reply Retweet Označi sa "sviđa mi se"
Xconomy 30. sij
Annovis Bio Gets $12M in IPO to Target Trio of Neurotoxic Proteins - by
Reply Retweet Označi sa "sviđa mi se"
Xconomy proslijedio/la je tweet
Dan Stanton 30. sij
Lack of good a factor for in investing $70-90m into internal PA gene therapy plant
Reply Retweet Označi sa "sviđa mi se"
Xconomy proslijedio/la je tweet
EBD Group 29. sij
Calling all 📢 Are you looking to engage with executives and ? Apply to pitch at this year’s Startup Spotlight during . The deadline to apply is this Friday, January 31! >>
Reply Retweet Označi sa "sviđa mi se"
Xconomy proslijedio/la je tweet
Frank Vinluan 29. sij
This drug didn't pan out treating a rare blood disorder or chronic kidney disease. But with positive topline Phs 2 data in , some now see blockbuster potential. shares shot up 50% Tues.
Reply Retweet Označi sa "sviđa mi se"
Xconomy proslijedio/la je tweet
Biotech Week Boston 29. sij
When developing a new therapy how do you keep in complete control of its manufacturing? This whitepaper looks at what to consider - whatever path you take.
Reply Retweet Označi sa "sviđa mi se"
Xconomy proslijedio/la je tweet
Big4Bio:Philly 29. sij
Attend the 14th Annual Hub and SPP Model Optimization event, which will feature manufacturers, pharmacies, PBMs and more, on February 24-26, 2020, at the Loews Philadelphia Hotel. Register today!
Reply Retweet Označi sa "sviđa mi se"
Xconomy 29. sij
. Ends Hepatitis B Work After Death in Clinical Trial - by
Reply Retweet Označi sa "sviđa mi se"